Valdis Pirags
Valdis Pirags
University of Latvia, Pauls Stradins Clinical University Hospital
Dirección de correo verificada de latnet.lv - Página principal
Título
Citado por
Citado por
Año
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a …
JA Dormandy, B Charbonnel, DJA Eckland, E Erdmann, ...
The Lancet 366 (9493), 1279-1289, 2005
44252005
Basal insulin and cardiovascular and other outcomes in dysglycemia
ORIGIN Trial Investigators
New England Journal of Medicine 367 (4), 319-328, 2012
14542012
n–3 fatty acids and cardiovascular outcomes in patients with dysglycemia
ORIGIN Trial Investigators
New England Journal of Medicine 367 (4), 309-318, 2012
7612012
Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular …
R Wilcox, MG Bousser, DJ Betteridge, G Schernthaner, V Pirags, S Kupfer, ...
Stroke 38 (3), 865-873, 2007
4802007
Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial
AK Sjølie, R Klein, M Porta, T Orchard, J Fuller, HH Parving, R Bilous, ...
The Lancet 372 (9647), 1385-1393, 2008
4522008
Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials
N Chaturvedi, M Porta, R Klein, T Orchard, J Fuller, HH Parving, R Bilous, ...
The Lancet 372 (9647), 1394-1402, 2008
4302008
Methylglyoxal modification of Nav1.8 facilitates nociceptive neuron firing and causes hyperalgesia in diabetic neuropathy
A Bierhaus, T Fleming, S Stoyanov, A Leffler, A Babes, C Neacsu, ...
Nature medicine 18 (6), 926, 2012
3532012
Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials
R Bilous, N Chaturvedi, AK Sjølie, J Fuller, R Klein, T Orchard, M Porta, ...
Annals of internal medicine 151 (1), 11-20, 2009
2902009
Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and …
JB Green, MA Bethel, SK Paul, A Ring, KD Kaufman, DR Shapiro, ...
American heart journal 166 (6), 983-989. e7, 2013
1392013
Design and baseline characteristics of participants in the R esearching cardiovascular E vents with a W eekly IN cretin in D iabetes (REWIND) trial on the cardiovascular …
HC Gerstein, HM Colhoun, GR Dagenais, R Diaz, M Lakshmanan, P Pais, ...
Diabetes, Obesity and Metabolism 20 (1), 42-49, 2018
1112018
CLINICAL PERSPECTIVE
HC Gerstein, RE Ratner, CP Cannon, PW Serruys, HM García-García, ...
Circulation 121 (10), 1176-1187, 2010
1002010
Initiation of insulin glargine therapy in type 2 diabetes subjects suboptimally controlled on oral antidiabetic agents: results from the AT. LANTUS trial
M Davies, F Lavalle‐González, F Storms, R Gomis, ...
Diabetes, Obesity and Metabolism 10 (5), 387-399, 2008
892008
Association of genetic variation in the organic cation transporters OCT1, OCT2 and multidrug and toxin extrusion 1 transporter protein genes with the gastrointestinal side …
L Tarasova, I Kalnina, K Geldnere, A Bumbure, R Ritenberga, ...
Pharmacogenetics and genomics 22 (9), 659-666, 2012
862012
Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo
R Bentley-Lewis, D Aguilar, MC Riddle, B Claggett, R Diaz, K Dickstein, ...
American heart journal 169 (5), 631-638. e7, 2015
852015
The DIabetic REtinopathy Candesartan Trials (DIRECT) Programme: baseline characteristics
DIRECT Programme Study Group
Journal of the Renin-Angiotensin-Aldosterone System 6 (1), 25-32, 2005
802005
Variation in the glucose transporter gene SLC2A2 is associated with glycemic response to metformin
K Zhou, SW Yee, EL Seiser, N Van Leeuwen, R Tavendale, AJ Bennett, ...
Nature genetics 48 (9), 1055-1059, 2016
782016
Pioglitazone use in combination with insulin in the prospective pioglitazone clinical trial in macrovascular events study (PROactive19)
B Charbonnel, R DeFronzo, J Davidson, O Schmitz, K Birkeland, V Pirags, ...
The Journal of Clinical Endocrinology & Metabolism 95 (5), 2163-2171, 2010
652010
The association of basal insulin glargine and/or n-3 fatty acids with incident cancers in patients with dysglycemia
L Bordeleau, N Yakubovich, GR Dagenais, J Rosenstock, J Probstfield, ...
Diabetes care 37 (5), 1360-1366, 2014
602014
The Diabetic Retinopathy Candesartan Trials (DIRECT) programme, rationale and study design
DIRECT Programme Study Group, N Chaturvedi
Journal of the Renin-angiotensin-aldosterone System 3 (4), 255-261, 2002
572002
Association of reduced glyoxalase 1 activity and painful peripheral diabetic neuropathy in type 1 and 2 diabetes mellitus patients
E Skapare, I Konrade, E Liepinsh, I Strele, M Makrecka, A Bierhaus, ...
Journal of Diabetes and its Complications 27 (3), 262-267, 2013
552013
El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.
Artículos 1–20